Andrea M. D’Armini
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerArticle | Published in 2014 in European Respiratory JournalGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.